Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
SCYX
SellSinkerSCYNEXIS, Inc. · Healthcare · United States · $54M · Avg Vol: $1M/d
COMPANY DESCRIPTION
SCYNEXIS, Inc. is a biotechnology company focused on developing and commercializing novel therapies to overcome and prevent difficult-to-treat infections. The company's primary asset is ibrexafungerp, a first-in-class oral antifungal agent that serves as a strong competitive moat against traditional, resistant fungal strains. It operates as a specialty pharmaceutical player targeting the high-unmet-need anti-infective market.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.1M | 140.1M | 3.7M | 20.6M | 59.4% | 19.2M | 0.6M | 6.7M | -43.1% |
| EPS | -4.84 | 5.25 | -1.68 | -1.36 | — | -0.91 | -4.08 | -2.52 | — |
| Shares | 9.9M | 9.9M | 9.9M | 5.4M | -45.2% | — | — | — | — |
| Debt | 48.6M | 15.1M | 16.3M | 2.2M | -64.5% | 1.9M | — | — | — |
| Equity | 3.2M | 73.0M | 55.1M | 49.4M | 148.1% | — | — | — | — |
| Op CF | -79.9M | 60.2M | -24.0M | -5.3M | — | -13.3M | — | — | — |
| Inv CF | -27.4M | -34.9M | 6.2M | 24.3M | — | — | — | — | — |
| Fin CF | 48.6M | -36.7M | -0.1M | -14.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SCYX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SCYX | SCYNEXIS, Inc.(you) | $54M | 31 | Sell |
| TLPH | Talphera, Inc. | $62M | 24 | Sell |
| CWEB.TO | Charlotte's Web Holdings, Inc. | $80M | 15 | Strong Sell |
| CPIX | Cumberland Pharmaceuticals Inc. | $127M | 38 | Hold |
| JUSH.CN | Jushi Holdings Inc. | $110M | 43 | Hold |
| SIGA | SIGA Technologies, Inc. | $220M | 30 | Sell |
| GRIN.CN | Grown Rogue International Inc. | $111M | 46 | Hold |
| ORGO | Organogenesis Holdings Inc. | $224M | 29 | Sell |
| CTOR | Citius Oncology, Inc. | $82M | 6 | Strong Sell |
| DERM | Journey Medical Corporation | $211M | 24 | Sell |
Peer medians: ROE -30.8% · P/E 27.0x · Gross margin 58.1%